Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-04-03
1997-07-01
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31165
Patent
active
056439652
ABSTRACT:
A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.
REFERENCES:
patent: 2937204 (1960-04-01), Harris et al.
patent: 3941783 (1976-03-01), Grega et al.
patent: 5171889 (1992-12-01), Anderson
patent: 5472983 (1995-12-01), Flitter et al.
Chugai Pharm., Chemical Abstracts, vol. 96, No. 26, 1982, p. 377.
Clark, Chemical Abstracts, vol. 98, No. 21, 1983, p. 620.
Clark et al, Chemical Abstracts, vol. 100, No. 25, 1984, p. 19.
Banasik et al., "Specific inhibitors of poly(ADP-Ribose) synthetase and mono(ADP-ribosyl)transferase" J. Biol. Chem. (1992) 267:1569-1575.
Beal, M.F. in Mitochondrial Dysfunction and Oxidative in Neurodegenerative Diseases, R.G. Landes Publications Austin, TX, (1995) pp. 53-61 and 73-99.
Bishop et al., "Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D.sub.2 receptors" J. Med. Chem. (1991) 34:1612-1624.
Burns, R.S., et al., "A Primate Model of Parkinsonism . . . " Proc. Natl. Acad. Sci USA (1983) 80:4546-4550.
Calne, D.B., "Treatment of Parkinson's Disease" NEJM (Sep. 30, 1993) 329:1021-1027.
El Tayar, et al., "Interaction of neuroleptic drugs with a rat striatal D-1 and D-2 dopamine receptors: a quantitative structure--affinity relationship study" Eur. J. Med. Chem. (1988) 23:173-182.
Gerlach, M. et al., "MPTP Mechanisms of Neurotoxicity and the Implications for Parkinson's Disease" European Journal of Pharmacology (1991) 208:273-286.
Heikkila, R.E., et al., "Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice" Science (Jun. 29, 1984) 224:1451-1453.
Hogberg et al., "Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners" J. Med. Chem. (1991) 34:948-955.
Kato, T., "Reaction of Triethyloxonium Fluoroborate with Acid Amide. III.sup.1) Formation of Quinazoline and 4H-3, 1-Benzoxazin-4-one Derivatives", Chem. Pharm. Bull. (1976) 24, 3:431-436.
Katopodis et al., "Novel substrates and inhibitors of peptidylglycine .alpha.-amidating monooxygenase" Biochemistry (1990) 29:4541-4548.
Langston, J.W., et al., "Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis" Science (Feb. 25, 1983) 219, 979-980.
Marsden, C.D., in "Review Article--Parkinson's Disease" Lancet (Apr. 21, 1990) 948-952.
Mizuno, Y., Mori, H., Kondo, T. "Potential of Neuroprotective Therapy in Parkinson's Disease" CNS Drugs (1994) 1:45-46.
Monkovic et al., "Potential non-dopaminergic gastrointestinal prokinetic agents in the series of substituted benzamides" Eur. J. Med. Chem. (1989) 24:333-240.
Rainnie et al., "Adenosine inhibition of mesopontine cholinergic neurons: implications for EEG arousal" Science (1994) 263:689-690.
Singer, T.P., et al., "Biochemical Events in the Development of Parkinsonism . . . " J. Neurochem. (1987) 1-8.
Flitter William
Garland William
Paylor Richard
Wilcox Allan
Centaur Pharmaceuticals, Inc.
Cintins Marianne M.
Jarvis William R. A.
LandOfFree
Aminobenzamide compounds for the treatment of neurodegenerative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminobenzamide compounds for the treatment of neurodegenerative , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminobenzamide compounds for the treatment of neurodegenerative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-597857